215

REFERENCES

[1] Chien, Y. W., 2003, “Oral drug delivery” in Novel drug deliverysystems, 2nd ed., Revised and Expanded, Informa health careUSA Inc., New York., 50, 139-196.

[2] Banker, G.S, and Rhodes C.T., 1996, “Modern Pharmaceutics”, 3rded., Marcel Dekker, New York pp. 678-721.

[3] Menon, A., Ritschel, W.A., and Sakr, A., 1994, “Development andevaluation of a monolithic floating dosage form for Furosemide”, J.Pharm. Sci., 83, pp.239–245.

[4] Malcolm, S.L., Allen, J.G., Bird, H., Quinn, N.P., Marion, M.H.,Marsden, C.D., and O’Leary C.G., 1987, “Single-dosepharmacokinetics of Madopar HBS in patients and effect of foodand antacid on the absorption of Madopar HBS in volunteers”, Eur.Neurol., 21, pp.28–35.

[5] Singh, B.N., and Kim, K.H., 2000, “Floating drug delivery systems:an approach to oral controlled drug delivery systems via gastricretention”, J. Cont.. Rel, 63, pp.235-259.

[6] Ichikawa, M., Watanabe,S., and Miyake, Y., 1989, “Granuleremaining in stomach”, U.S patent 4844905. July, pp.4.

[7] Dave, B.S., Amin, A.F., and Patel, M., 2002, “Gastroretentive drugdelivery system of ranitidine HCl formulation and in vitroevaluation”, AAPS Pharm. Sci. Tec., 5,pp. 1-10.

[8] Mastiholimath, V.S., Dandagi, P.M., Gadad, A.P., Mathews, R.,andKulkarni, A.R., 2008, “In vitro and in vivo evaluation of ranitidinehydrochloride ethyl cellulose floating microparticles”, J.microencapsulation,pp.1-8.

[9] Kopitar, Z., Vrhovac, B., Povsic, L., Plavsic, F., Francetic, I., andUrbancic, J.S., 1991, “The effect of food and metoclopramide andside effects of bromocriptine”, Eur. J. Drug Metab. Pharmacokinet,16, pp.177–181.

216

[10] Yang, L., Eshraghi, E., and Fassihi, R., 1999, “A new drug deliverysystem for the treatment of Helicobacter pylori associated gastriculcers: in vivo evaluation”, J. Controlled Release, 57, pp.215- 222.

[11] Rajnikanth, P.S., Balasubramnium, J., and Mishra,B., 2007.“Development and evaluation of a novel floating in situ gellingsystem of amoxicillin for eradication of H.pylori”, Int. J. Pharm.,335:114 -122, 2007. 3.061

[12] Sivakumar, R., Vithyalingam and Vilayat, A. S., 2010, “Criticalfactors in manufacturing multi-layer tablets - Assessing materialattributes, in-process controls, manufacturing process and productperformance”, Int. J. Pharm., 398, pp. 9-13.

[13] Quigly, E.M.M., Phillips, S.F., and Dent, J, 1984, “Distinctivepatterns of interdigestive motility at the canine ilio-colonicjunction”, Gastroenterology, 87, pp.836.

[14] Kellow, J.E., Borody, T.J., Philips, S.F., Tucker, R.L., and Hadda,A.C., 1986, “Human interdigestive motility: Variations in pattersfrom esophagus to colon” Gastroenterology, 91, pp.386.

[15] Mc Rae, S., Younger, K.,Thompson, D.G., and Wingate, D.L.,1982, “Sustained mental stress alters human jejuna motor activity”,Gut., 23, pp.404.

[16] Schwartz BJ, Connor RE. Optimization technique inPharmaceutical Formulations and processing, Drugs andPharmaceutical Sciences, In, Modern Pharmaceutics, Vol. 72, 3rdedition, (Banker, J. S., Rhodes, T. C., Eds.) Marcel Dekker, Inc,New York: 1996; 3: 727-754.

[17] Bolten S. "Optimization techniqes" in , Pharmaceutical statistics-Practical and clinical applications. Vol. 80, 3rd edition (Swarbrick,J., Ed.) Marcel Dekker Inc, New York. 1997; 3: 308-337.

[18] DeWever, I., Eeckhout, C., Vantrappen, G., and Hellemans, J.,1978, “Disruptive effect of test meals on interdigestive motorcomplex in dogs”, Am. J. Physiol., 235, pp. E661.

[19] Montgomery, D. C., 2004, "Introduction to factorial deign" in:Design and Analysis of Experiments, 5th ed. Wiley India Pvt. Ltd.,New Delhi, pp. 170-217.

217

[20] Barker T. Quality by experimental design., New York Basel:Marcel Dekker 1985: 3.

[21] Goran Alderborn, Christer Nystrom. Pharmaceutical powdercompaction technology. New York Basel: Marcel Dekker 1998:561.

[22] Swarbrick, J. and Boylan, J.C., “Optimization techniques informulation and processing. Encyclopedia of Pharmaceuticaltechnology., New York: Marcel Dekker.1994: 70.

[23] Ryden, T. and Jonsson, U.E., 1989, “A study of the absorption ofDiltiazem from the distal parts of the gastrointestinal tract”, Eur. J.Clin. Pharmacol., 36 (suppl), A243. (Abstract).

[24] Sheth, P.R., Tossounian, J. L., 1978, "Sustained releasepharmaceutical capsules" U S patent 4,126,672.

[25] Nur, A. O., Zhang, J.S., 2000, "Captopril floating and /orbioadhesive tablets: design and release kinetics" Drug Dev. Ind.Pharm. , 26: pp.965-969.

[26] Kouichi,N., Hiroyuki, Y., Hiroshi, F., Masaaki, O. and Syougo,I.,2001,"Evaluation of a floating dosage form of nicardipinehydrochloride and hydroxypropylmethylcellulose acetate succinateprepared using a twin-screw extruder" Int.J. Pharm., 218(1-2):pp.103-112.

[27] Streubel, A., Siepmann, J. and Bodmeier, R.,2003, "Floating matrixtablets based on low density foam powder: effect of formulationand process parameters on drug release", Eur. J. Pharm. Sci., 18:pp.37-45.

[28] Stockwell, S. F., Taylor, M.J., Hardy, J.G.,and Whelley,D.R.,1986, “Orally administered controlled drug delivery systemproviding temporal and spatial control J. Cont. Rel., 3,pp.167-175.

[29] Hilton, A. K, and Deasy, P. B., 1992, “In vitro and in vivoevaluation of an oral sustained release floating dosage form ofAmoxycyllin trihydrate”, Int. J. Pharm., 86, pp. 79-88.

[30] Atyabi, F., Sharma, H. L., Mohammed, H. A. H. and Fell, J. T.,1996, " In vitro evaluation of a novel gastro retentive formulationbased on ion exchange resins" J.Control. Release,42:pp.105-113.

218

[31] Penners, G., Lustig, K., and Jorg, P.V.G., 1997, “Expandablepharmaceutical forms”, US patent 5,651,985.

[32] Baumgartner, S., Kristen, J., Vreer, F., Vodopivec, P. and Zorko,B., 2000, "Optimization of floating matrix tablets and evaluation oftheir gastric residence time" Int. J. Pharm., 195: pp.125-135.

[33] Ozdemir, N., Ordu, S., and Ozkan, Y., 2000, “Studies of floatingdosage forms of Furosemide: in vitro and in vivo evaluation ofbilayer tablet formulation”, Drug Dev. Ind. Pharm., 26, pp. 857-866.

[34] Talwar, N., Sen, H., and Staniforth, J. N., 2001, “Orallyadministered controlled drug delivery system providing temporaland spatial control”, US patent 6261601.

[35] Moursy, N. M., Afifi, N. N., Ghorap, D. M. and El-saharty, J.,2003, "Formulation and evaluation of sustained release floatingcapsules of Nicardipine hydrochloride' Pharmazie, 58:pp.38-43.

[36] Strubing, S., Abbouda, T., Renata, C., and Metza, H., 2008, “Newinsights on poly (vinyl acetate)-based coated floating tablets:Characterisation of hydration and CO2 generation by benchtopMRI and its relation to drug release and floating strength”, Euro. J.Pharm. and Biopharm., 69, pp. 708-717.

[37] Janga, S., Lee, J., and Park, S., 2008, “Gastroretentive drugdelivery system of DA-6034, a new flavonoid derivative, for thetreatment of gastritis”, Int. J. Pharm., 356, pp. 88-94.

[38] Sungthongjeena, S., Sriamornsak, P., and Puttipipatkhachorn, S.,2008, “Design and evaluation of floating multi-layer coated tabletsbased on gas formation”, Euro. J. Pharm. and Biopharm., 69, pp.255-263.

[39] Rajinikanth, P., and Mishra, B., 2008, “Floating in situ gellingsystem for stomach site-specific delivery of clarithromycin toeradicate Helicobactor pylori”, J. Cont. Rel., 25, pp. 33-41.

[40] Mina, I. T., 2010, "Controlled-release effervescent floating matrixtablets of ciprofloxacin hydrochloride: Development, optimizationand in vitro–in vivo evaluation in healthy human volunteers"Eur.J.Pharm. Biopharm.,74(2):pp. 332-339.

219

[41] Liandong, H., Li, L., Xun, Y., Wei, L., Jianxue, Y., Yanhong, J.and Chuang, S. H. X.,2011, "Floating matrix dosage form fordextromethorphan hydrobromide based on gas forming technique:In vitro and in vivo evaluation in healthy volunteers" Eur. J.Pharm.Sci.,42(1-2):pp. 99-105.

[42] Hiroshi, I., Yoshiharu, M., Tsuneji, N., and Yoshiki, S., 1988,“Oral sustained release pharmaceutical preparation”, US patent4,777,033.

[43] Klemens, L., Penners, G., and Petersen-von, G. J., 1997,“Expandable pharmaceutical forms”, US patent 5,651,985

[44] Zeria Pharmaceutical Co., 1998, “A slow releasing pharmaceuticaloral formulation comprising a high viscosity water solublepolymer”, Japanese Patent No. 63-14715

[45] Timmins, P., Dennis, A. B. and Vyas, K. A., 2002, “Biphasiccontrolled release delivery system for high solubilitypharmaceuticals and method” U.S. Patent No. 6,475,521

[46] Abul, A K. , and Aomar, O., 2001,”Stabilized pharmaceuticalcomposition of a nonsteroidal anti-inflammatory agent and aprostaglandin”, U.S. Patent No. 6,287,600

[47] Nageswara, R.P., and Venkatesh, G. M.,1997, ”Pharmaceuticalthermal infusion process”, U.S. Patent No. 5,690,959

[48] Gordon, M., Sheth, N.V.,and Woolfe, A.J.,2001,“Anti-inflammatory pharmaceutical formulations”, U.S. Patent No.6,319,519

[49] Blume,R.W.,Davis,R.D., and Keyser, D. J.,2002, “Guaifenesinsustained release formulation and tablets”, U.S. Patent No.6,372,252

[50] Ziyaur, R., Mushir A., and Khar, R. K., 2006, “Design andevaluation of bilayer floating tablets of captopril”, Acta Pharm., 56,pp. 49-57.

[51] Narendra, C., Srinath, M.S., and Ganesh B., 2006, “Optimization ofbilayer floating tablet containing metoprolol tartrate as a modeldrug for Gastric retension”, AAPS PharmSciTech., 7(2), Article 34.

220

[52] Niranjan, C. P., Arethi, B., Hemant, K. P., Satya prakash, S., andVimala Devi, M., 2007, “Design and evaluation of sustained releasebilayer tablets of propranolol hydrochloride”, Acta Pharm., 57, pp.479-489.

[53] Ajit, K., and Manish, B., 2009, ”Development and evaluation ofregioselective bilayer floating tablets of Atenolol and Lovastatin forbiphasic release profile”, Iranian J. Pharm. Res., 8 (1):pp.15-25.

[54] Donald E. P., Whale B., and Geoghegan, E. J., , 1988, “Controlledabsorption Diltiazem pharmaceutical formulation”, U.S.Patent No.4,721,619

[55] Geoghegan, E. J., and Seamus, M., 1990, “Controlled absorptionDiltiazem formulation for once-daily administration”, U.S.PatentNo.4,894,240

[56] Nagaprasath, V. and Himadri, S, 2000,"Controlled drug deliverysystem of Diltiazem" US patent 6,074,669.

[57] Streubel, A., Siepmann, J. and Bodmeier, R., 2003, "Multiple unitgastroretentive drug delivery systems: a new preparation methodfor low density microparticles"J Microencapsul., 20(3): pp. 329-47

[58] Shimpi, S., Chauhan, B., Mahadik, K. R. and Paradkar,A.,2004,"Preparation and evaluation of Diltiazem hydrochloride-gelucire 43/01 floating granules prepared by melt granulation"AAPS PharmSciTech., 5:E43.

[59] Gambhire, M. N., Ambade, K.W., Kurmi, S.D., Kadam, V.J. andJadhav, K.R.,2007,"Development and in vitro evaluation of an oralfloating matrix tablet formulation of diltiazem hydrochloride"AAPS PharmSciTech., 8(3):E73.

[60] Kulkarni, A.S. and Bhatia, M.S.,2008, "Design of floating bilayertablets of diltiazem hydrochloride and lovastatin"PDA J. Pharm.Sci. Technol., 62(5):pp. 344-52.

[61] Liu, Q. andFassihi, R.,2009,"Application of a novel symmetricalshape factor to gastroretentive matrices as a measure of swellingsynchronization and its impact on drug release kinetics understandard and modified dissolution conditions"J. Pharm. Pharmacol.,61(7): pp.861-867.

221

[62] Raghavendra, V. K., Banappa, S. M., Srinivas, M. and Biswanath,S., "Interpenetrating polymer network microcapsules of gellan gumand egg albumin entrapped with Diltiazem-resin complex forcontrolled release application" Carbohydrate Polymers, 83: pp.1001-1007.

[63] Ahlneck, C. and Waltersson, J., 1986.“Factorial designs inpharmaceutical preformulation studies II. Studies on drug stabilityand compatibility in the solid state”. Acta Pharm. Suer., 23: pp.139-150.

[64] Bolton, S.. Reinstein, J. and Alobe, O., 1984, "Application offactorial designs in kinetic studies: Hydrolysis of benzylpenicillinsolutions." Int. J. Pharm. Tech. Prod. Mfr., 5:pp. 6-12.

[65] Gupta. P.K., Lam, F.C. and Hung, C.T.,1988, "Investigation of thestability of doxorubicin hydrochloride using factorial design" DrugDev. Ind. Pharm., 14 :pp. 1657-1671.

[66] Waltersson, J., 1986,"Factorial designs in pharmaceuticalpreformulation studies: Evaluation of the application of factorialdesign to a stability study of drugs in suspension form" ActaPharm. Suet., 23:pp.129-138.

[67] Devay, A., Kovacs. P. and Racz, I.,1985, "Optimization ofchemical stability of diazepam in the liquid phase by means of afactorial experimental design" Int. J. Pharm. Tech. Prod. Mfr., 6:pp.5-9.

[68] Malinowski, J.H. and Smith, W.E., 1975,"Use of factorial design toevaluate granulations prepared by spheronization" J. Pharm. Sci.,64: pp.1688-1692.

[69] Karabit, M.S., Juneskans, O.T. and Lundgren. P.,1989, "Factorialdesigns in evaluation of preservative efficacy" Int. J. Phcrrm.,56:pp.169-174.

[70] Nath, B.S. and Shingbal, D.M., 1974, "Factorial study ofpolyelectrolytes on in vitro drug release from eye drops" Indian J.Pharm., 36:pp.107-110.

[71] Nevin, C., Nurhan, E., and Ali, T., 1996, The preparation andevaluation of salbutamol sulphate containing poly(lactic acid-co-glycolic acid) microspheres with factorial design-based studies”,Int. J. Pharm.,136: pp.89-100.

222

[72] Gohel , M.C. , and Amin, A.F.,1998, “Formulation optimization ofcontrolled release diclofenac sodium microspheres using factorialdesign”, J. Control. Release, 51, pp.115-122.

[73] Li, S., Lin, S., Daggy, B. S., Mirchandani, H. L., and Chien, Y. W.,2003, “Effect of HPMC and Carbopol on the release and oatingproperties of Gastric Floating Drug Delivery System using factorialdesign” , Int. J. Pharm., 253,pp.13-22.

[74] Asuman, B., and Mehmet, O. S.,2005, “Formulation andinvestigation of 5-FU nanoparticles with factorial design-basedstudies”, I l Farmaco, 60, pp.840- 846.

[75] Rehab, N. S., Emad, B. B., and Raguia, A. S., 2011, “Developmentand optimization of a multiple-unit controlled release formulationof a freely water soluble drug for once-daily administration”, Int. J.Pharm., 405, pp.102-112.

[76] Grossman. E., and Messerli, F.H., 2004, “Calcium antagonists”,Prog. Cardiovasc. Dis., 47(1), pp. 34-57.

[77] Claas, S. A., and Glasser, S. P., 2005, “Long-acting Diltiazem HClfor the chronotherapeutic treatment of hypertension and chronicstable angina pectoris”, Expert Opinion on Pharmacotherapy, 6(5),pp. 765-776.

[78] Gabrielli, A., Gallagher, T. J., Caruso, L. J., Bennett, N. T., andLayon, A.J., 2001, “Diltiazem to treat sinus tachycardia in criticallyill patients: a four-year experience”, Critical Care Medicine, 29(10),pp. 1874-1879.

[79] Basile, J., 2004, “The role of existing and newer calcium channelblockers in the treatment of hypertension”, J. Clin. Hypertens.,6(11), pp. 621-629.

[80] Mills, K., Ansah, T. A., Ali, S. F., Mukherjee, S., and Shockley, D.C., 2007, “Augmented behavioral response and enhancedsynaptosomal calcium transport induced by repeated cocaineadministration are decreased by calcium channel blockers”, LifeSci., 81(7), pp. 600-608.

[81] Kishioka, S., Ko, M. C., and Woods, J. H., 2000, “Diltiazemenhances the analgesic but not the respiratory depressant effects ofmorphine in rhesus monkeys”, Eur. J. Pharmacol., 397(1), pp. 85-92.

223

[82] Verma, V., Mediratta, P. K., and Sharma, K. K., 2001,“Potentiation of analgesia and reversal of tolerance to morphine bycalcium channel blockers”, Indian J. Exp. Biol., 39(7), pp. 636-642.

[83] Nash, G. F., Kapoor, K., Saeb-Parsy, K., Kunanadam, T., andDawson, P. M., 2006, “The long-term results of Diltiazemtreatment for anal fissure”, Int. J. Clin. Pract., 60(11), pp. 1411-1413.

[84] Sajid, M. S., Rimple, J., Cheek, E., and Baig, M. K., 2008, “Theefficacy of Diltiazem and glyceryltrinitrate for the medicalmanagement of chronic anal fissure: a meta-analysis”, Int. J.Colorectal Dis., 23(1), pp. 1-6.

[85] Harwood, R.J., 2003, "Hypermelose" in Handbook ofpharmaceutical excipients, 4th ed., Raymond C. R., Paul, J. S. andPaul, J.W., Pharmaceutical Press, American Pharmaceuticalassociation, London, U.K. pp. 297-300.

[86] Parsons, D., 2003, "Carboxy methylcellulose" in Handbook ofpharmaceutical excipients, 4th ed., Raymond C. R., Paul, J. S. andPaul, J.W., Pharmaceutical Press, American Pharmaceuticalassociation, London, U.K. pp. 97-100.

[87] Weller, P. J., 2003, "Cellulose,Micorcrystalline" in Handbook ofpharmaceutical excipients, 4th ed., Raymond C. R., Paul, J. S. andPaul, J.W., Pharmaceutical Press, American Pharmaceuticalassociation, London, U.K. pp. 108-111.

[88] X He. and Kibee, A.H., 2003, "Crospovidone" in Handbook ofpharmaceutical excipients, 4th ed., Raymond C. R., Paul, J. S. andPaul, J.W., Pharmaceutical Press, American Pharmaceuticalassociation, London, U.K. pp. 184-185.

[89] Cable, C. G., 2003, "Sodium bicarbonate" in Handbook ofpharmaceutical excipients, 4th ed., Raymond C. R., Paul, J. S. andPaul, J.W., Pharmaceutical Press, American Pharmaceuticalassociation, London, U.K. pp. 552-555.

[90] Banker, G. S., and Anderson, N. R., 1987, “Tablets” in: The theoryand practice of industrial pharmacy, Lachmann, L., Liberman, H.A., and Kaing, J. L., eds., Varghese Publishing House, Bombay, pp.297-299.

224

[91] Indian Pharmacopoeia, 1996, The controller of publications: Delhi,Vol.II, pp. 734-736.

[92] Khan, G. M., 2001, “Controlled release oral dosage forms: somerecent advances in matrix type drug delivery systems”, TheSciences., pp. 350-354.

[93] Morkhade, D. M., 2006, “Gum copal and gum dammer novelmatrix forming material for sustained drug delivery”, Indian J.Pharm. Sci., 68, pp. 53-58.

[94] Higuchi, T., 1963, “Mechanism of rate of sustained-actionmedication”, J. Pharm. Sci., 52, pp. 1145-1149.

[95] Peppas, N. A., and Sahlin, J. J., 1989, “A simple equation for thedescription of solute release III. Coupling of diffusion andrelaxation”, Int. J. Pharm., 57, pp. 169-172.

[96] ICH Topic Q1A (R2), 2003, “Note for Guidance on StabilityTesting: Stability Testing of New Drug Substances and Products”,CPMP/ICH/2736/99.

[97] Grag, R., and Gupta, G. D., 2009, “Preparation and evaluation ofgastroretentive floating tablets of Silymarin”, Chem. Pharm. Bull.57(6), pp. 545-549.

[98] Peppas, N. A., 1985, “Analysis of Fickian and non-Fickian drugrelease from polymers”, Pharm. Acta. Helv., 60,pp.110– 111.

[99] Peppas, N. A., and Korsmeyer, R.W., 1986, “ Dynamicallyswelling hydro-gels in controlled release applications”, in: N.A.Peppas (Ed.),Hydrogels in Medicine and Pharmacy, Vol. 3, CRCPress,Boca Raton, pp. 109–136.

[100] Wang, T.T. , Kwei, T.K., Frisch, H.L., 1968, “Diffusion inglassypolymers III”, J. Polym. Sci. 7 pp. 2019–2028.

[101] Park, G.S., 1986, “Transport principles — solution, diffusion andpermeation in polymer membranes”, in: P.M. Bungay,H.K.Lonsdale, M.N. de Pinho (Eds.), Synthetic Membranes:Science, Engineering and Applications, D. Reidel PublishingCompany, Dordrecht, pp. 57–108.

[102] Frisch, H.L.,1980, “Sorption and transport in glassypolymers”,Polym. Eng. Sci. 20, pp. 2–13.

225

[103] Siepmann, J., Podual, K., Sriwongjanya, M., Peppas, N.A., andBodmeier, R., 1999, “A new model describing the swelling anddrug release kinetics from hydroxypropyl methylcellulose tablets”,J. Pharm. Sci. 88, pp.65–72.

[104] Ritger, P.L. , and Peppas, N.A. , 1987, “ A simple equation fordescriptionof solute release. I. Fickian and non-Fickian releasefrom non-swellable devices in the form of slabs, spheres, cylindersor discs”, J. Cont. Rel. 5, pp.23–36.

[105] Ritger, P.L. , and Peppas, N.A. , 1987,A simple equation fordescription of solute release II. Fickian and anomalous releasefrom swellable devices, J. Controlled Release 5, pp.37–42.

[106] Suryanarayana, S., John, C. K. L., Okponanadofa, E. and Kenneth,S. A., 1999, "Pharmacokinetics of a novel Diltiazem hydrochlorideextended-release tablet formulation for evening adminsitration"Am. J. Ther., 6: pp. 211-216.

226

LIST OF PUBLICATIONS

[1] Mohan Mothilal, Karunanidhi Santhana Lakshmi, 2011, “A Novelbilayer floating controlled release tablets (BFCRT) for twice dailyadministration of Diltiazem hydrochloride and the process thereof”Indian Patent application No. 71/CHE/2011, assigned to SRM Collegeof Pharmacy, SRM University, Kattankulathur.

227

VITAE

M.Mothilal was born on 17.05.1978 in Tindivanam, Villupuram

District, Tamil Nadu, India. He did his school education in St.Ann’s Higher

secondary school, Tindivanam, Villupuram District, Tamil Nadu, India. He

did his Bachelor Degree in Pharmacy, from Adhiparashakthi College of

Pharmacy, Melmaruvathur, Kancheepuram District, India, in the year 1995.

He took up higher education with scholarship for Masters Degree in

Pharmaceutics at Birla institute of Technology, Mesra, Ranchi, Jarkhand,

India after qualifying in GATE 1999 with a score of 94.14 and completed in

the year 2001. He took up the teaching profession as a Lecturer in SRM

College of Pharmacy, Kattankulathur, Kancheepuram District, India from

2001. He is at present working as Assistant Professor, SRM College of

Pharmacy, SRM University, Kattankulathur, Kancheepuram District, India.

To his credit he has 8 publications in both National and International Journals.

He is currently involved in Optimization of sustained release Bilayer Floating

Tablets of DLT using factorial design, drafted and applied his results as for

the Indian patent.